IRF4 and small cell lung carcinoma: Treatment of SCLC-P cells with aproteolysis targeting chimera (PROTAC) degrader of mSWI/SNF ATPases evictsPOU2F3 and its coactivators from chromatin and attenuates downstream signaling.B cell malignancies which are dependent on the POU2F1/2 cofactor, POU2AF1, arealso sensitive to mSWI/SNF ATPase degraders, with treatment leading to chromatineviction of POU2AF1 and IRF4 and decreased IRF4 signaling in multiple myelomacells.